


# FIGURE 1


1 2 3 4 5 6 7 8



$\beta$ -actin

FIGURE 2


1 2 3 4 5



IL-10



**FIGURE 3**



# FIGURE 4




FIGURE 5A

1 2 3 4 5






FIGURE 5B

1 2 3 4 5




80Kd----

34Kd----



**FIGURE 6**



# FIGURE 7

	<b>Leader</b> -----	
RAT	ATGGGCAGTCCGGTATT CAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T-----G-----	67
HUM	-----GA-----TG-C-----CT-----T-----G-T-----T-----G-----	55
	<b> V-like domain</b> -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----	189
RAT	AAAGCCGTAGGCCCAGAAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATT CAGCCCACCT	268
MOU	-----GA-----C-----A-----A-C-----TG-----	268
HUM	-----T-----A-----C-T-----G-GAA-----G-G-C-----TG-----	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG-----A-----G-----T-----CA	335
HUM	-T-G-A-----T-CC-----C-A-T-C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA-----GA-C-----C-----T-----CA-----A-A--	402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G	390
	<b> C-like domain</b> -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAAC TATTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C-CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGT CAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG-----T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGT CACCAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	--A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--	591
RAT	AAAGACCCCAA AACTCAGGTGGAAAGGAAGTGATCTGCCAGGTTT TATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC--	658
	<b> Transmembrane region</b> -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T-----A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--	725
	<b> Cytoplasmic region</b> -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C-----C-A-----A-----C-G-----T-----G-----C-A--	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	--A-----	837
HUM	---TG-----AG-T-----A-----C-----	825

# FIGURE 8

Leader sequence-----

-30 -1

RAT M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A

MOU -----L-----I---G-----

HUM - I - M - - - S - - - - V - - - V M - - - - V - - C - - -

|V-like domain (domain I) -----

RAT Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L

MOU -----A-----S-----

HUM ----Q-----E---Y-----K-----QNA----A--

31 \*\*

RAT I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y

MOU -----S-----T-----A--

HUM -----E N-----

61 \*\* \*\*

RAT K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M

MOU -----V-----W--S-----H I G-----

HUM ----K-----Q-----Q---T-----I---E-----

91\* \*\* |C-like domain (domain II)-----

RAT C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N

MOU -----T-----Q-----

HUM -----F G---I-----V-----S-----K

121 \*\*

RAT Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E

MOU -----T-----T-----

HUM F S-----M V F-----V P R-----

151\*\*

RAT N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K

MOU -----F-----

HUM ----V T L S--P-----H I-----N-----

181 \* |Transmembrane region -----

RAT E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L

MOU -----

HUM -----H---T--T--F---T V N---Y-----

211 |Cytoplasmic region -----

RAT L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S

MOU -----I-----

HUM -----V-----D-----L

241

RAT S Q G M Q R M K


MOU -----

HUM -----V--K---T

\* invariant cysteine residues: \*\* invariant asparagine (N-linked oligosaccharides)




**FIGURE 9**




CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

## UNITS ACTIVITY/CULTURE




**FIGURE 11**




**NPC from Flt3 treated mice**


FIGURE 12



**FIGURE 13**




**FIGURE 14**




NPC cells infused into renal transplant recipients

**FIGURE 15**




**FIGURE 16**



**Monoclonal antibodies added to culture**



**FIGURE 17**



**Monoclonal antibodies added to culture**

FIGURE 18A






FIGURE 18B



FOE027"4C51C660


## Effect of anti-OX2 on spontaneous abortions



**FIGURE 20**

**Effect of OX2:Fc on spontaneous abortions or renal allograft rejection**

**CBA with C57BL/6 grafts**



**Day of infusion/no. doses of OX2:Fc**




FIGURE 21

3

2

1




FGL 2



OX-2

FIGURE 22

# EXPRESSION OF OX-2 ON CYTOKERATIN- POSITIVE CELLS (TROPHOBLAST)



**FIGURE 23**

**EXPRESSION OF OX-2 ON CYTOKERATIN-POSITIVE CELLS (TROPHOBLAST)**

